Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its third annual Global Day of Good, with more than 1,000 employees volunteering simultaneously in their respe ...

BRIDGEWATER, N.J., Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, October 31, 2024, to discuss the financial results and p ...

—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib ...

Core Insights - Short interest is a significant technical indicator for contrarian investors, and it is a key component of Sehaeffers' Expectational Analysis® [1][2] - The analysis of short interest helps identify potential stock squeezes, where short sellers may be forced to cover their positions, driving stock prices higher [2][4] Group 1: Short Interest Analysis - The latest analysis by Senior Quantitative Analyst Rocky White focuses on stocks with high short interest, indicating potential for price increases if short sellers capitulate [2][3] - A table compiled by White lists various stocks with their short interest percentages, changes, and average short prices, highlighting significant short interest in the biotechnology sector [4][5] - Biotech stocks are particularly targeted by short sellers due to their volatility and the impact of drug pipeline developments on stock performance [4][6] Group 2: Specific Stock Insights - Insmed Inc (NASDAQ: INSM) has experienced a 9% drop in short interest, with current short interest accounting for 8% of its float, leading to a potential 55% loss for short sellers if they entered at $33.66 [5] - Viking Therapeutics Inc (NASDAQ: VKTX) and TG Therapeutics Inc (NASDAQ: TGTX) also show significant short interest, with 17.1% and 23.4% of their floats sold short, respectively, and potential losses of 55% and 47% for short sellers [5] - The SPDR S&P Biotech ETF (XBI) has seen an increase in short interest from 56% in May 2023 to 64.7% in September 2024, indicating a growing bearish sentiment in the biotech sector [6] Group 3: Future Projections - Projections for 2024 suggest significant potential gains for INSM, VKTX, and TGTX, with expected increases of 141%, 215%, and 30%, respectively, if short sellers begin to cover their positions [7]

Shares of Insmed (INSM) have more than doubled in market value in the past six months against the industry's 1.1% fall. During this timeframe, the stock has also outperformed the sector and the S&P 500. The surge in stock price can be attributed to the company's progress with its two pipeline candidates, brensocatib and treprostinil palmitil inhalation powder (TPIP), which are being developed in separate clinical studies targeting multiple lung disorders. The company's shares are also trading above the 50-d ...

Insmed Incorporated (NASDAQ:INSM) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Bryan Dunn – Head-Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer – Chief Medical Officer Conference Call Participants Jessica Fye – JPMorgan Ritu Baral – TD Cowen Joseph Schwartz – Leerink Partners Cameron Bozdog – Bank of America Jennifer Kim – Cantor Fitzgerald Leon Wang – Barclays Vamil Divan – Guggenheim Securities Li ...

Insmed (INSM) reported a loss of $1.94 per share in second-quarter 2024, wider than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter, the company posted a loss of $1.78. Insmed generated total revenues of $90.3 million during the quarter, up 17% year over year. Quarterly sales beat the Zacks Consensus Estimate of $88.0 million. Quarter in Detail In the reported quarter, total revenues were generated entirely from product revenues of its only-marketed drug, Arikayce, which is approved ...

Core Insights - Insmed reported $90.34 million in revenue for Q2 2024, a 17% year-over-year increase, and a surprise of +2.71% over the Zacks Consensus Estimate of $87.96 million [1] - The company reported an EPS of -$1.94, which is a decline from -$1.78 a year ago, and a surprise of -59.02% compared to the consensus EPS estimate of -$1.22 [1] Revenue Breakdown - Revenue from Japan was $21.11 million, slightly above the two-analyst average estimate of $21.04 million [3] - Revenue from Europe and the rest of the world was $5.44 million, exceeding the two-analyst average estimate of $4.31 million [4] - Revenue from the U.S. was $63.79 million, surpassing the average estimate of $61.72 million from two analysts [5] Stock Performance - Insmed shares have returned -2.9% over the past month, compared to a -6.5% change in the Zacks S&P 500 composite [5] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [5]

Company Performance - Insmed reported a quarterly loss of $1.94 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.22, and compared to a loss of $1.78 per share a year ago [1] - The company posted revenues of $90.34 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 2.71%, and up from $77.23 million in the same quarter last year [3] - Insmed has surpassed consensus revenue estimates two times over the last four quarters [3] Earnings Surprise and Outlook - The quarterly report represented an earnings surprise of -59.02%, with the company previously expected to post a loss of $1.22 per share but actually reporting a loss of $1.94 [2] - The current consensus EPS estimate for the upcoming quarter is -$1.02 on revenues of $92.89 million, and for the current fiscal year, it is -$4.71 on revenues of $353.25 million [8] Stock Performance and Industry Context - Insmed shares have increased approximately 129.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 9% [4] - The Medical - Biomedical and Genetics industry, to which Insmed belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [9]

Exhibit 99.1 Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024— —Primary Endpoint for ENCORE Study of ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Infection ...